8
Aug
2018

The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast

Today’s guest on The Long Run podcast is Ankit Mahadevia.

Mahadevia is the CEO of Cambridge, Mass.-based Spero Therapeutics. It’s an antibiotic developer. Specifically, it’s focused on new strategies for fighting gram-negative bacterial infections that are increasingly resistant to our existing set of antibiotics.

Ankit Mahadevia, CEO, Spero Therapeutics

Despite persistent warnings from global health authorities about the rise of multi-drug resistant bugs, and the need for new antibiotics to fight them, most major pharma companies have a limited appetite for this area of R&D, or have bailed out. There hasn’t been much money to make.

Mahadevia started thinking differently about the future of antibiotics a few years ago as an entrepreneur in residence at Atlas Venture. The team there came upon some research from Finland into a set of potentiator molecules, which they thought could create an opening on the surface of gram-negative bacteria. This is a pretty clever idea. Essentially, the thought is that these potentiators should allow many of our existing gram-positive directed antibiotics to get inside these hardy bugs and kill them. The science created enough of an opportunity for Spero to raise significant venture capital. I first wrote about the company when it raised its Series A venture capital round in June 2015. The company went public last November.

On this show, Mahadevia talks about a whole set of varied career experiences that led him to this moment in antibiotic R&D, along with some creative ideas being floated now to create new incentives to revitalize this important field. Anyone interested in creative thinking about staving off the post-antibiotic world will find this to be an interesting listen.

Now, join me and Ankit Mahadevia for The Long Run.

You may also like

Seeing Lots of Single Cells, Up Close: Serge Saxonov of 10X Genomics on The Long Run
Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run
Health Data That Can Meet Pharma Standards: Amy Abernethy on The Long Run
Telling Biotech Stories on TV: Listen to Meg Tirrell on The Long Run Podcast